This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
by Zacks Equity Research
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
Company News for Dec 28, 2023
by Zacks Equity Research
Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA
Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More
by Zacks Equity Research
Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.
Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug
by Zacks Equity Research
Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.
Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Iovance (IOVA) reports mixed second-quarter results as earnings beat estimates but sales miss the mark.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 41.98% and 96.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Iovance (IOVA) Gets Positive FDA Feedback on Lung Cancer Drug
by Zacks Equity Research
Based on feedback from the FDA, Iovance's (IOVA) ongoing mid-stage study on LN-145 in NSCLC could support approval under the accelerated pathway. IOVA also reports encouraging preliminary data.
Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study
by Zacks Equity Research
Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.
Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
by Zacks Equity Research
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
by Zacks Equity Research
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
by Zacks Equity Research
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More
by Kinjel Shah
Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
by Zacks Equity Research
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
by Zacks Equity Research
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
by Zacks Equity Research
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI